Can individuals co-infected with HIV and Hepatitis C initiate generic Sovaldi mixed therapy course?

Generic Sovaldi is an oral nucleotide analog inhibitor of the HCV NS5B polymerase enzyme. It plays a great role in HCV reproduction. Generic Sovaldi is a direct-acting agent, indicating that it intervenes directly with the HCV life cycle by inhibiting viral action of copying. Treatment course and length for generic Sovaldi are based on both viral genotype and patient population. Treatment response is different depending on baseline host and viral determinant factors. Monotherapy is not advised for treatment of CHC.

So, individuals co-infected with HIV and Hepatitis C may initiate generic Sovaldi mixed therapy course. Effectiveness of generic Sovaldi has been estimated in 223 patients with HCV and HIV-1 co-infection. The safety profile of those individuals with co-infection was the same as those registered in HCV mono-infected study. For those people getting Atazanavir as part of the antiretroviral treatment, 94% had increased level of total bilirubin (grade 3 or 4). None of the participants had concomitant transaminase elevated volumes though. Of the participants not receiving Atazanavir, grade 3 or 4 elevated total bilirubin was seen in 1.5% of subjects, which rate is similar to that researched with HCV mono-infected individuals receiving generic Sovaldi and Ribavirin in Phase 3 trials.

It is a primary mission of generic Sovaldi to mark the beginning of a new epoch in Hepatitis C treatment. Gilead is especially proud to have created a real masterpiece. This masterpiece is already bringing about this important therapeutic innovation and scientists extend their thanks to the many patients and physicians who cooperated with them on generic Sovaldi’s clinical investigations. John C. Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences expressed his and company’s sincere appreciation of strong belief and devotion in this hard work.

Individuals with HIV/HCV co-infection should be advised to avoid consuming alcohol and to use appropriate measures to prevent further transmission of HIV and/or HCV to other people. HIV/HCV-co-infected patients who are receptive to hepatitis A virus (HAV) or hepatitis B virus (HBV) infection should be treated with a vaccine to produce immunity against these viruses. It is a must! The patient’s role in this matter is to fight and not be passive. That is why any means are necessary in this battle.